Key Takeaways & Executive Findings
- •• Comprehensive risk factor management (hypertension, diabetes, dyslipidemia) is essential for stroke prevention. • Lifestyle modifications, including smoking cessation and physical activity, significantly reduce stroke risk. • Antiplatelet therapy is recommended for secondary prevention in non-cardioembolic stroke. • Novel oral anticoagulants are preferred over warfarin for stroke prevention in atrial fibrillation.
Abstract
Stroke is a major cause of death and disability worldwide, and its prevention is of paramount importance. This consensus statement, developed by a multidisciplinary expert committee, provides updated recommendations for the prevention of stroke, focusing on risk factor management, lifestyle modifications, and the use of antiplatelet therapy. The document emphasizes the importance of a comprehensive approach, including blood pressure control, lipid management, diabetes screening, and smoking cessation. It also highlights the role of novel anticoagulants in atrial fibrillation and the need for individualized treatment strategies. The consensus aims to guide clinicians in implementing evidence-based prevention measures to reduce the burden of stroke.
1. Introduction
Stroke remains a leading cause of mortality and long-term disability globally, with a particularly high burden in China. Despite advances in acute stroke treatment, prevention remains the most effective strategy to reduce the incidence and impact of stroke. This consensus statement, developed by a multidisciplinary expert committee, aims to provide updated, evidence-based recommendations for the prevention of stroke, addressing both primary and secondary prevention strategies.
The document synthesizes current evidence on risk factor management, including hypertension, diabetes, dyslipidemia, and atrial fibrillation, and emphasizes the importance of lifestyle modifications. It also discusses the role of antiplatelet and anticoagulant therapies, and highlights the need for individualized treatment approaches based on patient risk profiles. The goal is to offer practical guidance for clinicians to enhance stroke prevention in clinical practice.
Loading authentic research manuscript (Pages 1–5)...
Chinese Stroke Association Stroke Prevention Expert Committee (2026). Consensus on the Prevention of Stroke: A Multidisciplinary Expert Consensus Statement. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_211
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are the key recommendations for stroke prevention?
Key recommendations include strict blood pressure control, management of diabetes and dyslipidemia, smoking cessation, regular physical activity, and the use of antiplatelet therapy for secondary prevention. For patients with atrial fibrillation, anticoagulation with novel oral anticoagulants is preferred.
Who should receive antiplatelet therapy for stroke prevention?
Antiplatelet therapy is recommended for patients with a history of non-cardioembolic ischemic stroke or transient ischemic attack. Aspirin, clopidogrel, or the combination may be used depending on the clinical scenario and risk factors.
What is the role of novel oral anticoagulants in stroke prevention?
Novel oral anticoagulants (NOACs) are recommended for stroke prevention in patients with non-valvular atrial fibrillation. They have shown comparable or superior efficacy to warfarin with a lower risk of intracranial hemorrhage.
How can lifestyle modifications reduce stroke risk?
Lifestyle modifications such as smoking cessation, reducing alcohol intake, maintaining a healthy diet, and engaging in regular physical activity can significantly lower blood pressure, improve lipid profiles, and reduce the risk of stroke.
What is the significance of this consensus statement?
This consensus statement provides updated, evidence-based guidance for stroke prevention in China, integrating the latest research and expert opinion. It aims to standardize clinical practice and improve patient outcomes.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.